Sanofi's Commitment to Research and Identify Treatments for Cancer Patients
- Details
- Category: Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) announced that data from eight compounds in the company's robust oncology portfolio will be showcased in more than 100 abstracts at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 3-7, 2011.
SUTENT® Receives U.S. FDA Approval For Advanced Pancreatic Neuroendocrine Tumors
- Details
- Category: Pfizer
Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved SUTENT® (sunitinib malate) as the first anti-VEGF therapy to treat progressive, well-differentiated pancreatic neuroendocrine tumors (NET) in patients with unresectable locally advanced or metastatic disease.
Takeda to Acquire Nycomed - Transaction will Transform Takeda's Global Business
- Details
- Category: Takeda
Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) and Nycomed A/S ("Nycomed") jointly announced today that Takeda has reached an agreement with the shareholders of Nycomed in which Takeda will acquire the Zurich-headquartered company for 9.6 billion Euro on a cash-free, debt-free basis.
Roche to present significant progress in advanced skin, lung and ovarian cancers at ASCO
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that data showing new personalised therapeutic approaches for people with skin and lung cancer, plus new data with Avastin (bevacizumab) in ovarian cancer, will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Shire to establish new Regenerative Medicine business unit through cash acquisition of Advanced BioHealing, Inc.
- Details
- Category: Shire
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has signed an agreement to acquire Advanced BioHealing, Inc.
Pfizer To Present New Research From Fifteen Compounds
- Details
- Category: Pfizer
Pfizer Inc. will present more than 30 abstracts, including data from investigational compounds, axitinib,(1) crizotinib,(2) and bosutinib,(3) as well as data evaluating Sutent® (sunitinib malate), across multiple tumor types,(4,5) at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 3-7.
Patrick Dempsey Teams up With Breakaway from Cancer(R)
- Details
- Category: Amgen
Patrick Dempsey is speaking out to help connect cancer patients to the free resources available to them via Amgen's Breakaway from Cancer(R) initiative.
More Pharma News ...
- New drug applications submitted in the United States and Europe for vemurafenib in advanced skin cancer
- Pharmaceutical industry and university create Manchester Collaborative Centre for Inflammation Research
- Abbott's HUMIRA® (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study
- Health economics substudy of PLATO shows BRILIQUE to be a cost effective treatment versus generic Clopidogrel
- Sanofi-aventis and Medicines for Malaria Venture Join Forces to Develop Innovative Malaria Drugs
- Novartis gains FDA approval for Afinitor®
- FDA approves linagliptin tablets for the treatment of type 2 diabetes